Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR)

Antiviral Therapy

Volumn 9, Issue 2, 2004, Pages 213-220

  Wasmuth, Jan Christian ^a   La Porte, Charles J L ^b   Schneider, Katrin ^a   Burger, David M ^b   Rockstroh, Juergen K ^a  

^a UNIVERSITY OF BONN   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; CRYSTALLURIA; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSURIA; FEMALE; FLANK PAIN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY DISEASE; LIP DISEASE; MALE; MOUTH DISEASE; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADULT; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; INDINAVIR; MALE; RITONAVIR;

EID: 2342439457     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Burger DM, Hugen PW, Aarnoutse RE, Dieleman JP, Prins JM, van der Poll T, ten Veen JH, Mulder JW, Meenhorst PL, Blok WL, van der Meer JT, Reiss P & Lange JM. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. Journal of Acquired Immune Deficiency Syndromes 2001; 26:218-224.
2. Van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH & Hoetelmans RM. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antiviral Therapy 2001; 6:201-229.
3. Lichterfeld M, Nischalke HD, Bergmann F, Wiesel W, Rieke A, Theisen A, Fatkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H, Wasmuth JC & Rockstroh JK. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. HIV Medicine 2002; 3:37-43.
4. Voigt E, Wickesberg A, Wasmuth JC, Gute P, Locher L, Salzberger B, Wohrmann A, Adam A, Weitner L & Rockstroh JK. First-line ritonavir/ indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Medicine 2002; 3:277-282.
5. Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cah P, Fatkenheuer G, D'-Arminio-Monforte A, Casiro A, Reiss P, Burger DM, Stek M & Gatell JM. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003; 17:831-840.
6. Lamotte C, Peytavin G, Perre P, Chavanet P, de Truchis P, Gilquin J, Winter C, Katlama C & Farinotti R. Increasing adverse events (AE) with indinavir (IDV) dosages and plasma concentrations in four different ritonavir (RTV)-IDV containing regimen in HIV-infected patients. 2nd International workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, The Netherlands, April 2001. Abstract 4.1.
7. Lamotte C, Peytavin G, Perre P, Chavanet P, de Truchis P, Gilquin J, Winter C, Katlama C & Farinotti R. Increasing adverse events (AE) with indinavir (IDV) dosages and plasma concentrations in four different ritonavir (RTV)-IDV containing regimen in HIV-infected patients. 8th Conference on Retroviruses & Opportunistic Infections. Chicago, Ill., USA, February 2001. Abstract 738.
8. Ghosn J, Lamotte C, Ait-Mohand H, Wirden M, Agher R, Schneider L, Bricaire F, Duvivier C, Calvez V, Peytavin G & Katlama C. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17:209-214.
9. Aarnoutse RE, Wasmuth JC, Fatkenheuer G, Schneider K, Schmitz K, de Boo TM, Reiss P, Hekster YA, Burger DM & Rockstroh JK. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antiviral Therapy 2003; 8:309-314.
10. Hugen PW, Verweij-van Wissen CP, Burger DM, Wuis EW, Koopmans PP & Hekster YA. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography. Biomedical Sciences & Application 1999; 727:139-149.
11. Burger DM, de Graaff M, Wuis EW, Koopmans PP & Hekster YA. Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. Journal of Chromatography. B, Biomedical Sciences & Application 1997; 703:235-241.
12. Aarnoutse RE, Grintjes KJT, Telgt DSC, Stek M, Hugen PWH, Reiss P, Koopmans PP, Hekster YA & Burger DM. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clinical Pharmacology & Therapeutics 2002; 71:57-67.
13. Gibaldi M. Compartmental and noncompartmental pharmacokinetics. In Biopharmaceutics & Clinical Pharmacokinetics, 1991; pp. 14-23. Edited by M Gibaldi. Philadelphia/London: Lea & Febiger.
14. min is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. Journal of Acquired Immune Deficiency Syndromes 2002; 29:374-377.
15. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S & Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13:473-478.
16. Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Theisen A, Fatkenheuer G, Oette M, Carls H, Fenske S, Nadler M & Knechten H. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group. AIDS 2000; 14:1181-1185.
17. Acosta EP, Kakuda TN, Brundage RC, Anderson PL & Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clinical Infectious Diseases 2000; 30(Suppl. 2):S151-S159.
18. Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W & Hekster YA. Low plasma concentrations of indinavir are related to virologica treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Therapy 1998; 3:215-220.
19. Plosker GL & Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999; 58:1165-1203.
20. Hsu A, Granneman GR & Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clinical Pharmacokinetics 1998; 35:275-291.
21. Casado JL, Moreno A, Sabido R, Marti-Belda P, Antela A, Dronda F, Perez-Elias MJ & Moreno S. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clinical Trials 2000; 1:13-19.
22. Famularo G, Di Toro S, Moretti S & De Simone C. Symptomatic crystalluria associated with indinavir. Annals of Pharmacotherapy 2000; 34:1414-1418.